Endo International

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,.

Investors are cheering the drugmaker's settlement in principle of two lawsuits related to its opioid drugs.

Why Endo International Shares Are Soaring Again Today

Endo International on Tuesday said it had agreed to pay $10 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.

Drugmaker Endo to pay $10 million to settle opioid case ahead of trial

Shares of Endo International PLC soared 30% in active morning trading Tuesday, after the generic drug maker said it has reached a "settlement in principle" to resolve "track 1" opioid cases.

Endo's stock soars after settlement agreement on track 1 opioid cases

Mallinckrodt PLC

Investors appear to have some confidence that the companies will settle their opioid lawsuits.

Why Mallinckrodt and Endo International Shares Jumped Today

Is Endo International Holdings (ENDP) a great pick from the value investor's perspective right now? Read on to know more.

Is Endo International (ENDP) A Great Pick for Value Investors?

Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.

Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

Endo International plc (ENDP) CEO Paul Campanelli on Q2 2019 Results - Earnings Call Transcript

Shares fall even though the company posted better-than-expected results. What can explain the move?

Here's Why Endo International Is Falling Today

Endo (ENDP) delivered earnings and revenue surprises of 10.64% and 0.37%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Q2 Earnings and Revenues Surpass Estimates

Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Endo International (ENDP) Expected to Beat Earnings Estimates: Should You Buy?

Amneal Pharmaceuticals

Mylan

Teva Pharmaceutical

Pharmaceutical stocks Teva Pharmaceutical, Mylan, Endo and Amneal Pharmaceuticals may have to pay $8.5 billion in litigation costs surrounding the opioid epidemic, an analyst said Monday.

These Pharmas Could Be On The Hook For Billions In The Opioid Epidemic

These drug developers are all valued at less than four times this year's projected earnings per share.

3 Drug Stocks With Unimaginably Low P/E Ratios

Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers.

Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns

Bausch Health Companies Inc

Merck

Pharmaceutical and biotech stocks skidded Monday on expectations that President Donald Trump will sign an executive order to corral drug prices. This would be his 23rd executive order in 2019.

Medical Stocks Hammered As Trump Mulls Order To Corral Drug Prices

Investors liked a major credit agency's improved outlook for the drugmaker.

Why Endo International Stock Is Jumping Today

Endo is a well managed, organic R&D company returning to growth despite looming litigation risks on the horizon.

Endo Pharmaceuticals Should Survive Up To $3 Billion Worth Of Opioid Litigation, Making Shares Undervalued

Endo (ENDP) reported earnings 30 days ago. What's next for the stock?

Why Is Endo (ENDP) Down 38.9% Since Last Earnings Report?

I take a look at the reasons for the multi year slump in Endo shares.

Endo International: Cellulite Opportunity Vs. Opioid Overhang

Traders knock down the stock in response to an analyst downgrade.

Why Endo International Shares Are Under Pressure Today

Endo's (ENDP) earnings and revenues top expectations in the first quarter of 2019.

Endo (ENDP) Q1 Earnings & Revenues Beat Estimates

Endo International plc (ENDP) CEO Paul Campanelli on Q1 2019 Results - Earnings Call Transcript

Endo (ENDP) delivered earnings and revenue surprises of 26.19% and 4.07%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Beats Q1 Earnings and Revenue Estimates

Endo International plc will take its turn in the earnings confessional later this week, its first-quarter report set for before the market opens, Thursday, May 9.

News for Endo International Stock (ENDP)